Versant Ventures spinoff company Tempest Therapeutics secured $70 million in a Series B funding to advance the company’s immunotherapy pipeline.
The U.S. Food AND Drug Administration is working on around a dozen actions to boost use of cheaper versions of expensive biotech medicines, the head of the agency Scott Gottlieb said.
Outcome Health, a technology company that provides health education at the moment of care to improve patient outcomes, announced a partnership with the Colorectal Cancer Alliance to make patients aware of the signs and symptoms of colorectal cancer.
Roche’s shares dropped after the Swiss drugmaker told U.S.-based hemophilia advocacy groups that five patients treated with its medicine Hemlibra had died, while maintaining that the therapy was not the cause of the deaths.
A Tokyo court ruled that Shire’s claim against Swiss drugmaker Roche’s new Hemlibra hemophilia medicine should be dismissed, Roche’s Japanese subsidiary Chugai said.
Shares of AnaptysBio climbed after the company released positive interim data for its experimental peanut allergy treatment.
The U.S. Food and Drug Administration accepted Bristol-Myers Squibb’s supplemental Biologics License Application for Opdivo (nivolumab) with Yervoy (ipilimumab) for a type of colorectal cancer.
Omnicom Health Group announced that it has entered into a definitive agreement to acquire the Pharma Communications business in Japan of Elsevier, part of RELX Group.
GlaxoSmithKline opted to invest in its own consumer unit by acquiring the stake controlled by Swiss pharma giant Novartis.
An ischemic stroke occurs as a result of an obstruction within a blood vessel supplying blood to the brain and accounts for about 87 percent of all strokes, according to the American Stroke Association. A common treatment used to break up the clots and prevent brain damage has become mired in controversy.
Esperion Therapeutics’ experimental oral drug met the main goal of reducing cholesterol by 30 percent in patients who were already on another treatment to lower the risk of artery-clogging heart disease.
The U.S. Food and Drug Administration approved Sanofi’s Toujeo (insulin glargine 300 Units/mL) Max SoloStar, the highest capacity long-acting insulin pen that will be available on the market.
A U.S. jury ordered AbbVie Inc. to pay more than $3 million to a man who claimed the company misrepresented the risks of its testosterone replacement drug AndroGel.
Genentech’s Late-Stage Trial Data Shows Combination of Tecentriq and Avastin Helps NSCLC Patients Live Longer
Genentech Inc. is planning to seek regulatory approval for a blended lung cancer treatment following positive interim results from a late-stage trial that showed a combination of Tecentriq and Avastin plus chemotherapy enabled patients to live longer.
Ablynx’s anti-IL-6R nanobody vobarilizumab did not meet primary endpoints in a Phase II dosing study for lupus patients.
ImmunoGen released positive efficacy and tolerability data from its FORWARD II trial of mirvetuximab soravtansine in combination with Merck’s Keytruda in platinum-resistant epithelial ovarian cancer.
Protagonist Therapeutics Inc. discontinued a Phase IIb study for the experimental ulcerative colitis treatment PTG-100 following a review from an Independent Data Monitoring Committee (DMC).
Biohaven Pharmaceutical Holding said the company’s treatment for acute migraine cleared two late-stage studies, but investors worried about its commercial viability as the efficacy data failed to distinguish from Allergan’s rival treatment.
Brite Media Group, a leading out-of-home advertising company, announced the acquisition of Mesmerize Marketing.
Israel will invest nearly 1 billion shekels ($287 million) in a project to make data about the state of health of its population available to researchers and private companies, Prime Minister Benjamin Netanyahu said.